Herne Bay mum hit by car sent flying off bike during charity ride kentonline.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kentonline.co.uk Daily Mail and Mail on Sunday newspapers.
Cambridgeshire trial will see if tapeworm drug can protect against Covid-19 cambridge-news.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cambridge-news.co.uk Daily Mail and Mail on Sunday newspapers.
UNI91103,developed by UNION therapeutics A/S,selected as first agent for prophylactic COVID-19 “PROTECT-V” study in high-risk patients UNI91103 is a nasal spray delivering niclosamide - a potent inhibitor of SARS-CoV-2 with in-vitro potency >40x higher than remdesivir - to the nasal cavityUNI9110.
He added: “I’m aware I am lucky.
“I am retired, living in a house with a lovely big garden in a remote location, so in lockdown I could garden, walk the dogs, run around the garden to keep fit.
“I don’t have the financial pressures of a younger man with small children, concerned not just for health but also finances.
“I am also aware that if I was a high-shielder living in a city, I would not have been so relaxed.”
Niclosamide is usually taken in tablet form to treat intestinal worms. For the clinical trial, it will be re-formulated into a nasal spray.
/PRNewswire/ UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to.